An atypical neuroleptic drug in the treatment of behavioural disturbances and psychotic symptoms in elderly people.
The present study is a retrospective study of remoxipride therapy. A total of 103 patients, 65 years or older, with a DSM-III-R diagnosis of dementia or delirium, were included. They had all been treated with remoxipride because of psychotic symptoms or behavioural disturbances. The dose range of remoxipride was 50-300 mg, the median dose being 75 mg. The clinical effect was rated as good in two thirds of the patients, and side-effects were noted in one fourth. When psychomotor hyperactivity was the dominating problem, a good effect was rated in 81% of the patients. Side-effects were few and mild, the most common being tiredness; only 5 patients showed extrapyramidal symptoms.
Robertsson
B
B
Department of Psychiatry and Neurochemistry, Mölndal Hospital, Sweden.
Karlsson
I
I
Eriksson
L
L
Olsson
J O
JO
Olofsson
H
H
Jacobsson
N O
NO
Arnell
G
G
D000368:Aged; D000369:Aged, 80 and over; D000375:Aging / Q000523:psychology*; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003693:Delirium / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D001523:Mental Disorders / Q000188:drug therapy*; D011618:Psychotic Disorders / Q000188:drug therapy*; D017330:Remoxipride / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012189:Retrospective Studies; D016896:Treatment Outcome
D014150:Antipsychotic Agents; D017330:Remoxipride